Alembic Pharma Gets USFDA Nod for Generic Bromfenac Ophthalmic Solution
By Rediff Money Desk, New Delhi Jul 09, 2024 14:13
Alembic Pharmaceuticals receives USFDA approval for its generic Bromfenac ophthalmic solution, indicated for post-cataract surgery inflammation and pain treatment.

New Delhi, Jul 9 (PTI) Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic Bromfenac ophthalmic solution, which is indicated for the treatment of postoperative inflammation and pain in patients who have undergone cataract surgery.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Prolensa Ophthalmic Solution, 0.07 per cent of Bausch & Lomb Incorporated (Bausch), it added.
Bromfenac Ophthalmic Solution 0.07 per cent is a Nonsteroidal Anti-inflammatory Drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, the company said.
It has an estimated market size of USD 168 million for 12 months ended March 2024, Alembic said citing IQVIA data.
The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Prolensa Ophthalmic Solution, 0.07 per cent of Bausch & Lomb Incorporated (Bausch), it added.
Bromfenac Ophthalmic Solution 0.07 per cent is a Nonsteroidal Anti-inflammatory Drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, the company said.
It has an estimated market size of USD 168 million for 12 months ended March 2024, Alembic said citing IQVIA data.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.57 ( -9.52)
- 60265410
- Vodafone Idea L
- 8.27 (+ 0.73)
- 44071594
- YES Bank Ltd.
- 17.67 ( -0.56)
- 16081247
- G G Engineering
- 1.06 ( -4.50)
- 15019273
- Remedium Lifecare
- 3.97 (+ 4.75)
- 11827509
MORE NEWS

India-EU FTA Talks: Next Round in March
India and the EU will hold the next round of talks on the proposed free trade agreement...
ABB India Profit Surges 54% to Rs 532 Cr in Q4
ABB India reported a 54% jump in net profit to Rs 532 crore in the December quarter,...

Magellanic Cloud Targets Rs 600 Crore Revenue...
Magellanic Cloud, a Hyderabad-based IT services provider, aims to achieve Rs 600 crore...